In HNSCC, both pembrolizumab and nivolumab (PD-1 inhibitors) have gained FDA approval for use in recurrent/metastatic HNSCC after progression through platinum-based chemotherapy (9–11). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.